Back to Search
Start Over
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.
- Source :
-
Clinical and molecular hepatology [Clin Mol Hepatol] 2022 Oct; Vol. 28 (4), pp. 773-789. Date of Electronic Publication: 2022 Aug 08. - Publication Year :
- 2022
-
Abstract
- Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs.
- Subjects :
- Humans
Obesity complications
Obesity epidemiology
Risk Factors
Hepacivirus
Triglycerides
Lipoproteins, LDL
Cholesterol
Carcinoma, Hepatocellular complications
Liver Neoplasms complications
Liver Neoplasms epidemiology
Non-alcoholic Fatty Liver Disease complications
Non-alcoholic Fatty Liver Disease epidemiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Diabetes Mellitus epidemiology
Dyslipidemias complications
Liver Diseases, Alcoholic
Hepatitis C complications
Subjects
Details
- Language :
- English
- ISSN :
- 2287-285X
- Volume :
- 28
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical and molecular hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 35934813
- Full Text :
- https://doi.org/10.3350/cmh.2021.0383